<div id="readability-page-1">Rakuten Investment Management Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 65,400 shares of the biopharmaceutical company's stock, valued at approximately $7,259,000.<div>Get Gilead Sciences alerts:</div><ul><li>3 Cash-Flow Machines Investors May Want Heading Into 2026</li></ul>A number of other institutional investors also recently modified their holdings of GILD. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the third quarter worth $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth $27,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences during the second quarter worth about $30,000. Finally, Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 94 shares in the last quarter. 83.67% of the stock is owned by institutional investors. <h2>Gilead Sciences Price Performance</h2>NASDAQ:GILD opened at $131.14 on Friday. Gilead Sciences, Inc. has a 52-week low of $92.21 and a 52-week high of $133.10. The company has a market cap of $162.70 billion, a P/E ratio of 20.33, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock's 50-day simple moving average is $123.76 and its 200 day simple moving average is $118.46. <ul><li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li></ul>Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analysts' expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business's quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year. <h2>Gilead Sciences Announces Dividend</h2>The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Monday, December 15th. Gilead Sciences's payout ratio is presently 48.99%. <h2>Insider Activity</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul>In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00. Following the transaction, the chief executive officer owned 566,698 shares of the company's stock, valued at $70,740,911.34. The trade was a 1.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 141,757 shares of company stock valued at $17,569,112. 0.27% of the stock is owned by corporate insiders. <h2>Key Headlines Impacting Gilead Sciences</h2>Here are the key news stories impacting Gilead Sciences this week:<ul> <li>Positive Sentiment: NEJM published full Phase 3 ASCENT‑04/KEYNOTE‑D19 results showing Trodelvy (sacituzumab govitecan) + Keytruda met the primary endpoint with a ~35% PFS improvement (HR 0.65), supporting the combo as a potential new first‑line standard in PD‑L1+ metastatic TNBC — a major commercial catalyst for Gilead’s oncology franchise. NEJM ASCENT-04 Results</li> <li>Positive Sentiment: Multiple outlets (PharmaLetter) summarized the NEJM publication and reinforced the significance of the clinical data for Trodelvy’s uptake and reimbursement discussions — amplifying the immediate market reaction. PharmaLetter Trodelvy-Keytruda NEJM Coverage</li> <li>Positive Sentiment: Rothschild &amp; Co Redburn raised its price target to $159 and kept a &#34;buy&#34; rating — a bullish institutional signal that supports further upside and likely contributed to buying momentum. Rothschild &amp; Co Redburn Price Target</li> <li>Positive Sentiment: Investor commentary highlighting margin expansion and stronger free cash flow as underappreciated drivers has supported fundamental buying beyond the clinical news. Seeking Alpha on Margins &amp; Cash Flow</li> <li>Neutral Sentiment: Market write‑ups and a Zacks note pointed out that GILD outpaced the broader market today — useful for context but largely descriptive of price action rather than new fundamental change. Zacks: Why GILD Outpaced Market</li> <li>Neutral Sentiment: Valuation and technical pieces note recent share‑price strength and improved momentum — these can attract traders but don’t alter the clinical/commercial thesis. Yahoo Valuation Check</li> <li>Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at ~$123.50), reducing his stake by ~36% — an insider sale that can prompt short‑term investor concern about timing or confidence (though insiders sell for many non‑signal reasons). SEC Form 4 — Bluestone</li> <li>Negative Sentiment: RBC’s price target (~$103, sector perform) remains well below current levels — a conservative analyst view that could limit upside if other firms adopt similar stances. RBC Price Target Note</li> </ul><h2>Analysts Set New Price Targets</h2>Several equities research analysts have recently issued reports on the stock. HSBC increased their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a &#34;hold&#34; rating in a research report on Wednesday, December 10th. Truist Financial began coverage on Gilead Sciences in a research note on Monday, November 24th. They issued a &#34;buy&#34; rating and a $140.00 price target on the stock. Citigroup boosted their price target on Gilead Sciences from $135.00 to $140.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, January 7th. Wells Fargo &amp; Company increased their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, December 10th. Finally, Royal Bank Of Canada lifted their target price on Gilead Sciences from $100.00 to $103.00 and gave the company a &#34;sector perform&#34; rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of &#34;Moderate Buy&#34; and an average target price of $133.52.Read Our Latest Research Report on GILD<h2>Gilead Sciences Profile</h2> (Free Report)Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world. Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.<h2>Featured Articles</h2><ul><li>Five stocks we like better than Gilead Sciences</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Do not delete, read immediately</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Executive Order 14330: Trump’s Biggest Yet</li></ul>Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).<img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2>Before you consider Gilead Sciences, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

Rakuten Investment Management Inc. acquired 65,400 shares of Gilead Sciences, Inc. (NASDAQ:GILD) in Q3, valued at approximately $7.26 million, according to a recent SEC filing. Other institutional investors also increased their stakes in Gilead. The company reported a quarterly EPS of $2.47, exceeding estimates, with revenue of $7.77 billion. Gilead announced a quarterly dividend of $0.79 per share, yielding 2.4%. Insider trading activity included sales by CFO Andrew D. Dickinson and CEO Daniel Patrick O'day, with a total of 141,757 shares sold in the last three months.

Market Beat

SPDR S&P Biotech

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares US Pharma

iShares Global Healthcare

VG Health

Gilead Sciences, Inc.

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Gilead Sciences

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Rakuten Investment Management Inc. Purchases New Shares in Gilead Sciences, Inc. $GILD